Mangiferin and norathyriol acting on Alzheimer’s disease biomarkers: acetylcholinesterase, β-secretase (BACE-1), and amyloid β-peptide
Journal of Pharmacy and Pharmacology · 30.10.2025 · 77 (11) · 1513-1522
DOI: 10.1093/jpp/rgaf055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, online erschienen am 11.08.2025. Verfasst von Tiago Bento de Oliveira und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculdade de Ciências Farmacêuticas, Universidade Estadual de Campinas, Candido Portinari Street, 200, Campinas, Sao Paulo 13083-871, Brazil. Hauptthemen laut MEDLINE: Alzheimer Disease, Xanthones, Amyloid Precursor Protein Secretases, Amyloid beta-Peptides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Objectives
Mangiferin, a chemical constituent of Mangifera indica, has been the subject of extensive investigation due to its diverse biological activities, as detailed in numerous scientific studies. Its aglycone, norathyriol, has similarly garnered attention from researchers. In furtherance of our ongoing research goals, this article presents an evaluation of these compounds in relation to biomarkers associated with Alzheimer’s disease.
Methods
The inhibition of acetylcholinesterase (AChE) and β-secretase (BACE-1), as well as the aggregation of the amyloid beta (Aβ)42 peptide, was assessed using Ellman’s colourimetric method, fluorescence resonance energy transfer (FRET), and thioflavin-T fluorescence emission, respectively. Key findings Mangiferin exhibited no inhibitory effect on AChE, whereas norathyriol demonstrated an inhibitory concentration (IC50) of 6.23 μM. Molecular docking revealed that the mangiferin-AChE and mangiferin-BACE-1 complexes did not interact with sites related to enzyme activity. In contrast, norathyriol showed favourable interactions with Asp72 at the peripheral site of AChE and formed significant interactions with BACE-1 through hydrogen bonds, as suggested by molecular docking. The IC50 of norathyriol for BACE-1 inhibition was found to be 9.75 μM. The reduction in Aβ42 aggregation by norathyriol was only 28%.
Conclusion
We conclude that norathyriol is a promising prototype for drug development aimed at treating Alzheimer’s disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculdade de Ciências Farmacêuticas, Universidade Estadual de Campinas, Candido Portinari Street, 200, Campinas, Sao Paulo 13083-871, Brazil.
- Departamento de Química Orgânica e Inorgânica, Universidade Federal do Ceará, Campus do Pici - Bloco 935 superior - Laboratório de Produtos Naturais e Biotecnologia (LPNBio), ZC 60451-970, Universidade Federal do Ceará,…
ORCID-Profile: Wanda P Almeida
Zitieren
APA
de Oliveira, T. B., Galeriani, A. C. B., Rodrigues de Souza, J. R., Kawano, D. F., Trevisan, M. T. S., & Almeida, W. P. (2025). Mangiferin and norathyriol acting on Alzheimer’s disease biomarkers: acetylcholinesterase, β-secretase (BACE-1), and amyloid β-peptide. Journal of Pharmacy and Pharmacology, 77(11), 1513-1522. https://doi.org/10.1093/jpp/rgaf055
Vancouver
de Oliveira TB, Galeriani ACB, Rodrigues de Souza JR, Kawano DF, Trevisan MTS, Almeida WP. Mangiferin and norathyriol acting on Alzheimer’s disease biomarkers: acetylcholinesterase, β-secretase (BACE-1), and amyloid β-peptide. Journal of Pharmacy and Pharmacology. 2025;77(11):1513-1522. doi:10.1093/jpp/rgaf055
BibTeX
@article{deOliveira2025,
author = {de Oliveira, Tiago Bento and Galeriani, Ana Claudia Beneton and Rodrigues de Souza, José R and Kawano, Daniel F and Trevisan, Maria Teresa Salles and Almeida, Wanda P},
title = {Mangiferin and norathyriol acting on Alzheimer’s disease biomarkers: acetylcholinesterase, β-secretase (BACE-1), and amyloid β-peptide},
journal = {Journal of Pharmacy and Pharmacology},
year = {2025},
volume = {77},
number = {11},
pages = {1513--1522},
doi = {10.1093/jpp/rgaf055}
}
EUVIMED